Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Tregs
Biotech
Retension, Lilly-backed TRex both plan to join IPO stampede
Eli Lilly-backed TRex Bio and hypertension-focused Retension Pharmaceuticals are the latest biotechs to set out plans to go public this year.
James Waldron
Sep 21, 2026 4:29am
Quell halts transplant trial to focus on 'chill not kill' Treg
Feb 5, 2026 6:00am
Zag Bio emerges with $80M funding for Tregs diabetes candidate
Oct 28, 2025 7:00am
BMS sold on GentiBio's regulatory T-cells, inks $1.9B deal
Aug 10, 2022 7:00am
